Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
Blood|October 27, 2007
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group reportNancy D Doolittle, Lauren E Abrey, Tamara N Shenkier, et al.
BMC Surgery|January 28, 2014
Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinomaCatharina Ruf, Oliver Thomusch, Matthias Goos, et al.
BMC Cancer|March 31, 2019
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patientsElisabeth Schorb, Juergen Finke, Gabriele Ihorst, et al.
Journal of Glaucoma|August 30, 2014
The trabectome as treatment option in secondary glaucoma due to intraocular lymphomaChristian van Oterendorp, Thomas Ness, Gerald Illerhaus, et al.
Deutsches Arzteblatt International|July 13, 2018
The Diagnosis and Treatment of Primary CNS LymphomaLouisa von Baumgarten, Gerald Illerhaus, Agnieszka Korfel, et al.
Haematologica|January 2, 2008
High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous systemGerald Illerhaus, Fabian Müller, Friedrich Feuerhake, et al.
Cancer Chemotherapy and Pharmacology|September 15, 2006
Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphomaDavid E Gerber, Stuart A Grossman, Tracy Batchelor, et al.
Leukemia & Lymphoma|July 24, 2018
A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cellsAnna Brandt, Jakob Matschke, Wilfried Fehrle, et al.
Journal of Neuro-Oncology|September 27, 2007
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphomaAlfredo D Voloschin, Rebecca Betensky, Patrick Y Wen, et al.
Cancer Research|April 19, 2007
Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumabMascha Binder, Friederike-Nora Vögtle, Stefan Michelfelder, et al.
Pageof 12